BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. today announced several changes in its commercial operations intended to support rapid growth and payer adoption of its growing portfolio of products targeting lung cancer. Wendy Blosser is joining the company, and will serve as Vice President, Sales driving the sales of Biodesix’ expanding portfolio of blood-based tests in oncology. In addition, two other leaders have stepped into newly created roles: Jasmine Gruia-Gray, PhD. has assumed management of all marketing activities as the Vice President of Marketing and Robin Cowie has been promoted to the newly created role of Vice President, Reimbursement and Health Care Economics.
Biodesix CEO David Brunel noted that, “We are tremendously excited to have Wendy, a proven sales executive with an impressive track record, driving adoption of diagnostics testing in oncology. With VeriStrat® having been adopted into the NCCN Guidelines® and with additional VeriStrat indications and new products slated for release in 2015, we have also expanded the roles of Robin and Jasmine to facilitate payer and clinical adoption.”
Help employers find you! Check out all the jobs and post your resume.
